Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5microg of hST2-Fc (or control Fc protein), 2microg of hIL-33-His (Prod. No. AG-40A-0042) (or control His protein), and protein G resin (or anti-H
Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5microg of hST2-Fc (or control Fc protein), 2microg of hIL-33-His (Prod. No. AG-40A-0042) (or control His protein), and protein G resin (or anti-H
IL-33 (human) (rec.) (His)
AG-40A-0042
Overview
- SupplierAdipoGen Life Sciences
- Product NameIL-33 (human) (rec.) (His)
- Delivery Days Customer10
- CertificationResearch Use Only
- Concentration1 mg/ml
- Estimated Purity>90%
- FormulationLiquid
- Protein IDQ2YEJ5
- Protein NameInterleukin-33
- Scientific DescriptionInterleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis. - Protein. Human IL-33 (aa 112-270) is fused at the C-terminus to a His-tag. Source: E. coli. Endotoxin content: <1EU/microg purified protein (LAL test; Lonza). Liquid. 0.2microm-filtered solution in 55mM TRIS-Cl, pH 8.2, containing 150mM NaCl. Binds to human ST2. Purity: >90% (SDS-PAGE). Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352202